Human Protein Z as the Second Known Heme-Binding Protein from the Endogenous Blood Coagulation Inhibitor System

Sep 30, 2026

Uploaded by Terk

Human Protein Z (PZ) is a vitamin-K-dependent anticoagulant cofactor that lacks enzymatic activity yet binds the PZ-dependent protease inhibitor (ZPI) and supports factor Xa inactivation. The study investigates heme-triggered effects within the blood coagulation inhibitor network, comparing PZ with activated protein C (APC), the first known endogenous heme-binding anticoagulant. Using PZ-derived peptide models and in silico analyses, a specific heme-binding site is identified, with protein-level binding resembling APC. PZ’s thrombin inhibition increases in the presence of heme, while aPTT-based assays show dampened anticoagulant function, indicating potential heme-induced prothrombotic consequences.

LanguageEnglish

CategoryHealthcare

FormatPDF

Pages9

Reading Time23 min

AccessFree to download

Introduction

Heme release and pathological consequences

Known heme-binding coagulation proteins and inhibitors

Rationale for studying Protein Z (PZ)

ChemBioChem Research Article [doi.org/10.1002/cbic.202500636](doi.org/10.1002/cbic.202500636) [www.chembiochem.org](www.chembiochem.org) Human Protein Z as the Second Known Heme-Binding Protein from the Endogenous Blood Coagulation Inhibitor System Paula Lindemann and Marie-T. Hopp* | Protein Z (PZ) is a vitamin-K-dependent glycoprotein that serves as an anticoagulant cofactor in blood. Although it is homologous to the serine proteases of blood coagulation, PZ has no enzymatic activity. It binds to the PZ-dependent protease inhibitor and supports inactivation of factor Xa. In addition, an inhibitory effect on thrombin is described. Clinically, changed PZ levels increase the risk for thrombosis. The related activated protein C (APC) is described as the first anticoagulant protein that binds heme under hemolytic conditions leading to its inhibition. However, the network of inhibitors of blood coagulation is still underexplored with respect to their role in heme-triggered effects and the regulation thereof. PZ seems to be an interesting candidate | in this context due to its homology to APC. Using PZ-derived peptides as models for potential heme-binding sites in PZ together with in silico studies, one specific heme-binding site in PZ is identified. Binding studies on protein level demonstrate binding characteristics similar to APC. Finally, the inhibitory effect of PZ toward thrombin is increased in the presence of heme, providing also insights into a potential functional consequence of the PZ–heme interaction. In addition, the anticoagulant function of PZ is dampened in the presence of heme in an aPTT-based clotting assay, suggesting a tendency toward heme-induced prothrombotic actions. In future, this will support mapping the diverse effects of heme within blood coagulation. | | --- | --- | | 1. Introduction
Intravascular hemolysis, the premature rupture of red blood cells and subsequent release of hemoglobin into blood plasma, displays a pathological event with profound implications for vascular homeostasis. [1,2] The heme moiety in hemoglobin rapidly oxidizes, thus leading to its release from the globin chains. While hemoglobin and heme levels are usually tightly regulated by scavenger proteins, the heme-binding capacity of these proteins becomes overwhelmed in severe hemolytic conditions, such as in patients suffering from β-thalassemia, sickle cell disease paroxysmal nocturnal hemoglobinuria, or hemolytic transfusion reactions, which leads to intravascular accumulation of labile heme. [3–5] In this context, concentrations in the high micromolar range have been reported. [4,6,7] Excess labile heme, however, contributes to oxidative stress, endothelial activation, proinflammatory reactions, and a strong prothrombotic state that exacerbates vascular dysfunction and tissue injury. [8–11] Although a direct interference of heme within the blood coagulation system was
P. Lindemann, M.-T. Hopp
Bioorganic Chemistry, Chemistry Department
Institute for Integrated Natural Sciences
University of Koblenz
Universitätsstraße 1, 56070 Koblenz, Germany
[E-mail: mhopp@uni-koblenz.de](E-mail: mhopp@uni-koblenz.de)
Supporting information for this article is available on the WWW under [https://](https://)[ ](https://)[doi.org/10.1002/cbic.202500636](doi.org/10.1002/cbic.202500636)
© 2025 The Author(s). ChemBioChem published by Wiley-VCH GmbH. This isan open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. | suggested already in 1911 when heme injections caused extravasating bleeding in guinea pigs and rabbits,[12] direct interactions of heme with the blood clotting components were only proposed in 1983.[13] Until today, coagulation factor VIII (FVIII) and fibrinogen are the only clotting factors discovered as heme-binding proteins so far.[14–17] FVIII binds up to seven

FAQs

What role does Protein Z (PZ) play in blood coagulation?

PZ is a vitamin-K-dependent glycoprotein that functions as an anticoagulant cofactor by supporting ZPI-mediated inactivation of factor Xa and is described to influence thrombin inhibition.

Why is heme considered important in blood coagulation regulation?

Excess labile heme contributes to oxidative stress, endothelial activation, proinflammatory reactions, and a prothrombotic state, and its direct interference with coagulation components is discussed as a mechanism for dysregulation.

How was heme-binding in PZ investigated and what was found?

The work uses PZ-derived peptides as models for potential heme-binding sites combined with in silico studies, identifying a specific heme-binding site. Binding studies on the protein level show characteristics similar to APC.

Sep 30, 2026

Uploaded by Terk